Q&A with Greg Irace,sanofi-aventis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Greg Irace,sanofi-aventis
Greg Irace, president of sanofi-aventis, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 5, pp. 96

Q&A with
Greg Irace, president of sanofi-aventis


Greg Irace
PharmTech:
What is the biggest industry challenge you're now facing?

Irace:
I'd say the biggest challenge we're all facing is change. From the end of the blockbuster era, to the impact of healthcare reform, to a challenging regulatory environment and the changing dynamics between patients, payors, and providers, the entire context in which we operate is changing.

Globally, sanofi-aventis has taken many steps to stay ahead of the curve and address these challenges. First, we are diversifying our business. We now consider ourselves not just a pharmaceutical company, but a diversified healthcare company. In addition to our pharmaceutical and vaccine businesses, we have built a significant presence in consumer health, animal health, and emerging markets. We are also being more strategic about how we allocate resources; we're now concentrating on high-growth areas, including diabetes, oncology, and atrial fibrillation. Ultimately, we work with our partners to protect health and enhance life. I believe these moves will set us up for long-term sustainable growth.

PharmTech:
Do you see a new industry trend emerging?

Irace:
We are excited about the trend of using a decentralized approach. Companies are forming disease-based units with their own experts dedicated to research and development, regulatory affairs, marketing, and sales. The goal of this approach is to bring the best and brightest minds and methods to bear early on in the development process of a potential treatment and to leverage those resources throughout the product's life cycle.

Recognizing patients' evolving needs and the challenging environment in which we are operating, sanofi-aventis US has adopted a decentralized model. We hope this approach will result in greater efficiencies—improving the likelihood of success by focusing efforts on fewer projects with greater potential—and improved innovation, ultimately benefiting patients.

We're also energized by developments in the medical-device arena that have the potential to change the way patients manage their conditions. sanofi-aventis US offers various devices to simplify insulin use for patients.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here